Sort
48,018 grants matching “immunotherapy”
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance
$629,409Linghua Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Innate-adaptive crosstalk in protective and vaccine-induced immunity to TB
$629,390Jyothi Rengarajan · Emory University · R01 · FY2017 · AI
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study
$629,354Rebecca Ashare · State University Of New York At Buffalo · U01 · FY2025 · CA
Focal Adhesion Kinase inhibition for dual targeting of osteosarcoma cells and the tumor microenvironment to prevent metastasis
$629,341Daniel Patrick Regan · Colorado State University · R37 · FY2025 · CA
Genetically engineered mouse model to improve therapy of NUT carcinoma
$629,248Christopher A French · Brigham And Women'S Hospital · R01 · FY2024 · CA
Engineered âmuco-trappingâ antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections
$629,240Samuel Lai · Univ Of North Carolina Chapel Hill · R01 · FY2024 · AI
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL
$629,238Manuel L Penichet · University Of California Los Angeles · R01 · FY2020 · CA
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
$629,224Cesar M Castro · Massachusetts General Hospital · R01 · FY2024 · CA
TUMOR IMMUNOTHERAPY WITH BIODEGRADABLE MICROSPHERES
$629,093Thomas F Conway · Therapyx, Inc. · R44 · FY2006 · CA
Phenotypic variability within isogenic population of lymphocytes
$629,064Grãgoire Altan-Bonnet · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Evaluation and Treatment of Obsessive Compulsive and Related Disorders
$629,055Susan Swedo · National Institute Of Mental Health · ZIA · FY2019 · MH
Targeting Neoantigens in Triple Negative Breast Cancer
$629,038William E Gillanders · Washington University · R01 · FY2019 · CA
Project 3: Spherical Nucleic Acids as Immunotherapeutic Agents for Prostate Cancer
$628,901Chad A. Mirkin · Northwestern University At Chicago · U54 · FY2017 · CA
MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1
$628,850Pawel Kalinski · Roswell Park Cancer Institute Corp · P50 · FY2015 · CA
EGFR Peptides as Vaccines in Anti-Tumor Immunity
$628,721Mark J. Mamula · L2 Diagnostics, Llc · R42 · FY2010 · CA
Clinical Development of Immunotherapies for Rare Hematologic Maligancies
$628,666Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
$628,557Hongjun Wang · Medical University Of South Carolina · R01 · FY2023 · DK
Targeting Latency Switch in EBV+ Lymphomas
$628,505Lisa Giulino Roth · Weill Medical Coll Of Cornell Univ · R37 · FY2024 · CA
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors
$628,499Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2024 · CA
Defining the role of tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial Disparities
$628,469Mark P Rubinstein · Ohio State University · R01 · FY2025 · CA
Radiation and dendritic cells to hepatomas to improve immunotherapy response
$628,467Sean S Park · Mayo Clinic Rochester · R01 · FY2025 · CA
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
$628,386Jin Wang · Baylor College Of Medicine · R01 · FY2025 · CA
Unlocking the Immunobiology of Conventional Dendritic Cells to Augment T Cell Activation in Glioblastoma
$628,373Gavin Peter Dunn · Massachusetts General Hospital · R01 · FY2025 · NS
An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection
$628,362Steven Carl George · University Of California At Davis · R01 · FY2022 · EB
IDO1 and Immunotolerance in Glioblastoma
$628,320Derek Alan Wainwright · Northwestern University At Chicago · R01 · FY2022 · NS